{"nctId":"NCT03471078","briefTitle":"Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers","startDateStruct":{"date":"2018-10-12","type":"ACTUAL"},"conditions":["Chemotherapy-induced Thrombocytopenia"],"count":122,"armGroups":[{"label":"Avatrombopag","type":"EXPERIMENTAL","interventionNames":["Drug: Avatrombopag"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Oral Tablet"]}],"interventions":[{"name":"Avatrombopag","otherNames":[]},{"name":"Placebo Oral Tablet","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women greater than or equal to 18 years of age;\n* A diagnosis of ovarian, lung (small cell or non-small cell) or bladder cancer requiring systemic chemotherapy\n* Participant receiving a chemotherapy regimen given in a 21 or 28-day cycle, including 1 or more of the following agents or class of agents:\n\n  * Nucleoside analog, including gemcitabine and fluorouracil;\n  * Carboplatin or cisplatin;\n  * Anthracycline; or\n  * Alkylating agent;\n* Participant experienced severe thrombocytopenia, defined as 2 platelet counts \\<50 x 109/L measured at least 24 hours apart, during the qualifying chemotherapy cycle, of their current chemotherapy regimen\n* ECOG performance status \\<=2\n\nExclusion Criteria:\n\n* Participant has experienced \\>=Grade 2 CIT other than during the current chemotherapy treatment regimen within 6 months of Screening;\n* Participant has any history of hematologic malignancies, including leukemia, myeloma, myeloproliferative disease, lymphoma, or myelodysplastic diseases;\n* Participant has received \\>2 previous lines of chemotherapy or is receiving whole brain radiation during the study treatment period;\n* Participant has a known medical history of genetic prothrombotic syndromes\n* Participant has a history of arterial or venous thrombosis within 3 months of screening;\n* Use of vitamin K antagonists;\n* Participant has previously received a thrombopoietin receptor agonist or recombinant human thrombopoietin for the treatment of CIT within 3 months of screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Who do Not Require Platelet Transfusion, Dose Reduction in Chemotherapy by 15%, or Chemotherapy Delay by >=4 Days","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Severe Thrombocytopenia Defined as a Platelet Count <50 x 10^9/L","description":"The duration of severe thrombocytopenia is defined as the total number of days with a platelet count \\<50×10\\^9/L during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day of Cycle X+2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"5.53"},{"groupId":"OG001","value":"4.7","spread":"6.56"}]}]}]},{"type":"SECONDARY","title":"Change in Platelet Count From Baseline (Nadir)","description":"Comparison of avatrombopag 60 mg vs. placebo, adjusted for the number of chemotherapy agents currently receiving per IWRS (1, ≥2).\n\nCycle X nadir is defined as the lowest platelet count value prior to the first dose of study drug; Cycle X+1 nadir is defined as the lowest platelet count value during the period after post-chemotherapy study drug treatment in Cycle X+1 through Chemotherapy Day in Cycle X+2.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.5","spread":"61.85"},{"groupId":"OG001","value":"29.1","spread":"39.48"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Did Not Have Major or Non-major Clinically Relevant Bleeding During the Period After Post-chemotherapy Study Drug Treatment in Cycle X+1 Through Chemotherapy Day of Cycle X+2.","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":82},"commonTop":["Anaemia","Neutropenia","Leukopenia","Thrombocytopenia","Nausea"]}}}